Abiomed Announces First FDA-Approved AbioCor(R) Implant at UMDNJ-Robert Wood Johnson Medical School and Robert Wood Johnson University Hospital

Published: Jun 24, 2009

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ: ABMD), today announced the successful implant of its AbioCorĀ® Total Replacement Heart, performed at Robert Wood Johnson University Hospital by Mark Anderson, M.D., associate professor of surgery at UMDNJ-Robert Wood Johnson Medical School and chief of the section of cardiac surgery at both the medical school and Robert Wood Johnson University Hospital. This is the first AbioCor implant since the completion of clinical trials and Humanitarian Device Exemption (HDE) approval from the U.S. Food and Drug Administration (FDA) on September 5, 2006.

Back to news